PK measures in space and time: Summary of high-resolution methods

Dear All: 

I recently sent around discussions of ways to measure/estimate drug concentrations both in living animals (aptamer-based probes, Kevin Plaxco’s group) and with sufficient spatial resolution to permit construction of 2d/3d drug concentration maps (MALDI-MSI, David Perlin’s group).

In the context of our efforts to learn to better apply PK-PD (e.g., the 14-15 June 2017 NIAID PK-PD workshop), these notes generated a lot of interest and in particular Ed Weinstein (FDA) made me aware of a book chapter in which he and his co-authors had looked at a range of such techniques.

Finding this intriguing, I worked with Kevin, David, and Ed to prepare a summary of the range of current techniques for doing something that you could loosely call PK in high resolution by time and/or space. Several ways of categorizing the methods are shown in the table below and you’ll find more details on each in this downloadable summary document. It’s fascinating to see them side-by-side and realize the wealth of opportunities that exist.

Each approach has strengths and weaknesses but I must say that MALDI-MSI and aptamer-based probes really standout as exciting new tools by offering strong spatial information (MALDI-MSI) or easily obtained continuous drug measures (aptamer-based probes) based in both cases on measurements of the unmodified analyte

Overview of techniques: Specialized probe and/or modified analyte vs. general approach to detection of unmodified analytes

Continuous, with
potential for in vivo
Single* time point
Offers
spatial
resolution
Fluorescent probeHyperpolarized NMR/MRIPET ImagingPhotoacoustic imagingLow energy (3H or 14C) radio-labeled analyte
with Whole-Body AutoradiographyMALDI-MSILaser-capture microdissection
Single*
site
Aptamers on a probeMicrodialysisGrind tissue & assay extract

*Of course, any single time point or single site method could be extended by doing serial sampling but there are practical limits to how much of this you can do.

Rough rank order of spatial imaging resolution methods:

  1. Higher resolution: MALDI-MSI, autoradiography
  2. Lower resolution: Fluorescent probe, Hyperpolarized NMR/MRI, PET Imaging, Photoacoustic imaging, Laser-capture microdissection

Absolute analyte concentration data: (1) Aptamers on a probe, (2) Microdialysis (with difficulty), (3) Laser-capture microdissection, and (4) Grind tissue & assay extract

If this intrigues, you may also want to look both at this book and PK-specific chapter within it:

  1. Book: Imaging Infections : From Bench to Bedside. S. K. Jain.: https://link.springer.com/book/10.1007%2F978-3-319-54592-9
  2. Chapter in said book Ordonez, A. A., L. E. Bambarger, S. K. Jain and E. A. Weinstein (2017). Biodistribution and Pharmacokinetics of Antimicrobials. Imaging Infections : From Bench to Bedside. S. K. Jain. Cham, Springer International Publishing: 209-222. :https://link.springer.com/chapter/10.1007/978-3-319-54592-9_10

And to round out this summary of PK-related ideas, you might also want to review the material from

MANY thanks to Ed, David, and Kevin for provoking this interesting exploration!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog.html

Upcoming meetings of interest to the AMR community:

Share

Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on whatsapp
Share on reddit

PAR Foundation grants: Early career support, prevention of AMR in the elderly

Dear All, The Stockholm-based PAR Foundation (aka, the Foundation to Prevent Antibiotic Resistance) has announced two groups of grant opportunities. First, early career grants of up to ~€30k are available to support 1-year projects on prevention of antibiotic resistance. What: “The aim of this call is to improve the ability and interest of promising early-career individuals

BARDA and NIAID RFPs addressing bacterial, fungal, and viral threats

Dear All, When it rains, it pours … and sometimes in a good way! Today saw the release of requests for proposals by NIAID and BARDA for therapeutics (antibacterial, antifungal, antiviral), vaccines (again, all 3 areas), and diagnostics. It’s an impressive list of opportunities that covers both biothreat pathogens as well as NIAID’s list of

ARPEGE: New €17m French Consortium tackles economics, diagnostics, and therapeutics

Dear All, On 6 Jan 2022, we had the announcement of the creation of in France of the ARPEGE consortium (AppRoche théraPeutique Economique & diaGnostique de l’antibiorésistancE) or “Economic, diagnostic and therapeutic approach to antibiotic resistance.” Somebody definitely had fun with that acronym! Here’s what you need to know: The French government is providing €9m of

Scroll to Top